Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations

British Journal of Haematology

Volumn 160, Issue 1, 2013, Pages 25-34

  Bench, Anthony J ^a   White, Helen E ^b,c   Foroni, Letizia ^d   Godfrey, Anna L ^e   Gerrard, Gareth ^d   Akiki, Susanna ^f   Awan, Abida ^g   Carter, Ian ^h   Goday Fernandez, Andrea ^a   Langabeer, Stephen E ⁱ   Clench, Tim ^j   Clark, Jordan ^k   Evans, Paul A ^l   Grimwade, David ^m   Schuh, Anna ⁿ   McMullin, Mary F ^o   Green, Anthony R ^e   Harrison, Claire N ^p   Cross, Nicholas C P ^b,c  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b SALISBURY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^g MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^h NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

ⁱ ST JAMES S HOSPITAL   (Ireland)

^j BRISTOL ROYAL INFIRMARY   (United Kingdom)

^k UK NEQAS for Leucocyte Immunophenotyping   (United Kingdom)

^l ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^m KING'S COLLEGE LONDON   (United Kingdom)

ⁿ CHURCHILL HOSPITAL   (United Kingdom)

^o QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^p GUY S HOSPITAL   (United Kingdom)

more..

Author keywords

JAK2; Molecular diagnosis; MPL; Myeloproliferative neoplasm

Indexed keywords

BCR ABL PROTEIN; GENOMIC DNA; JANUS KINASE 2;

ARTICLE; BCR ABL1 GENE; CELL ISOLATION; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; EXON; FALSE POSITIVE RESULT; GENE; GENE FREQUENCY; GENE FUNCTION; GENE MUTATION; GENETIC SCREENING; GRANULOCYTE; HUMAN; JANUS KINASE 2 GENE; MOLECULAR DIAGNOSIS; MOLECULAR PATHOLOGY; MPL GENE; MYELOPROLIFERATIVE NEOPLASM; ONCOGENE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UNITED KINGDOM;

BONE MARROW NEOPLASMS; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; GREAT BRITAIN; HUMANS; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS;

EID: 84870851579     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12075     Document Type: Article

References (87)

1. Albiero, E., Bernardi, M., Madeo, D., Ruggeri, M. & Rodeghiero, F. (2008) A new TMHA-DHPLC assay for the rapid mutation screening of JAK2 exon 14 in myeloproliferative disorders. American Journal of Hematology, 83, 603-604.
2. Antonioli, E., Carobbio, A., Pieri, L., Pancrazzi, A., Guglielmelli, P., Delaini, F., Ponziani, V., Bartalucci, N., Tozzi, L., Bosi, A., Rambaldi, A., Barbui, T. & Vannucchi, A.M. (2010) Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. Haematologica, 95, 1435-1438.
3. Asimakopoulos, F.A., Gilbert, J.G.R., Aldred, M.A., Pearson, T.C. & Green, A.R. (1996) Interstitial deletion constitutes the major mechanism for loss of heterozygosity on chromosome 20q in polycythemia vera. Blood, 88, 2690-2698.
4. Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A. & Erber, W.N.; The Cancer Genome Project & Green AR (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 1054-1061.
5. Beer, P.A., Campbell, P.J., Scott, L.M., Bench, A.J., Erber, W.N., Bareford, D., Wilkins, B.S., Reilly, J.T., Hasselbalch, H.C., Bowman, R., Wheatley, K., Buck, G., Harrison, C.N. & Green, A.R. (2008) MPL mutations in myeloproliferative disorders: analysis of the PT-1 Cohort. Blood, 112, 141-149.
6. Beer, P.A., Jones, A.V., Bench, A.J., Goday-Fernandez, A., Boyd, E.M., Vaghela, K.J., Erber, W.N., Odeh, B., Wright, C., McMullin, M.F., Cullis, J., Huntly, B.J., Harrison, C.N., Cross, N.C. & Green, A.R. (2009) Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. British Journal of Haematology, 144, 904-908.
7. Boyd, E.M., Bench, A.J., Goday-Fernandez, A., Anand, S., Vaghela, K.J., Beer, P., Scott, M.A., Bareford, D., Green, A.R., Huntly, B. & Erber, W.N. (2010) Clinical utility of routine MPL exon 10 analysis in the diagnosisof essential thrombocythaemia and primary myelofibrosis. British Journal of Haematology, 149, 250-257.
8. Campbell, P.J., Scott, L.M., Buck, G., Wheatley, K., East, C.L., Marsden, J.T., Duffy, A., Boyd, E.M., Bench, A.J., Scott, M.A., Vassiliou, G.S., Milligan, D.W., Smith, S.R., Erber, W.N., Bareford, D., Wilkins, B.S., Reilly, J.T., Harrison, C.N. & Green, A.R. (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet, 366, 1945-1953.
9. Cankovic, M., Whiteley, L., Hawley, R.C., Zarbo, R.J. & Chitale, D. (2009) Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory. American Journal of Clinical Pathology, 132, 713-721.
10. Cario, H., Goerttler, P.S., Steimle, C., Levine, R.L. & Pahl, H.L. (2005) The JAK2 V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. British Journal of Haematology, 130, 795-805.
11. Cazzola, M. (2007) Somatic mutations of JAK2 exon 12 as a molecular basis of erythrocytosis. Haematologica, 92, 1585-1589.
12. Chaligné, R., Tonetti, C., Besancenot, R., Roy, L., Marty, C., Mossuz, P., Kiladjian, J.J., Socié, G., Bordessoule, D., Le Bousse-Kerdilès, M.C., Vainchenker, W. & Giraudier, S. (2008) New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia, 22, 1557-1566.
13. Chen, Q., Lu, P., Jones, A.V., Silver, R.T. & Wang, Y.L. (2007) Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. The Journal of Molecular Diagnostics, 9, 272-276.
14. Clark, J.R., Jack, A.L., Barnett, D. & Reilly, J.T. (2012) JAK2 V617F false negative rate in the UK NEQAS LI programme. British Journal of Haematology, 157(Suppl 1), 56.
15. Cleyrat, C., Jelinek, J., Girodon, F., Boissinot, M., Ponge, T., Harousseau, J.L., Issa, J.P. & Hermouet, S. (2010) JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5. Leukemia, 24, 1069-1073.
16. Dentali, F., Squizzato, A., Brivio, L., Appio, L., Campiotti, L., Crowther, M., Grandi, A.M. & Ageno, W. (2009) JAK2 V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood, 113, 5617-5623.
17. Denys, B., El Housni, H., Nollet, F., Verhasselt, B. & Philippé, J. (2010) A real-time polymerase chain reaction assay for rapid, sensitive, and specific quantification of the JAK2 V617F mutation using a locked nucleic acid-modified oligonucleotide. The Journal of Molecular Diagnostics, 12, 512-519.
18. Etheridge, L., Corbo, L.M., Kaushansky, K., Chan, E. & Hitchcock, I.S. (2011) A novel activating JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis (fET) via mechanisms distinct from JAK2 V617F. Blood, 118, 123. (ASH Annual Meeting Abstracts).
19. Ghaderi, M., Stromberg, O. & Porwit, A. (2008) Rapid real-time PCR assay for detection of MPL W515L mutation in patients with chronic myeloproliferative disorders. International Journal of Laboratory Hematology, 32, 122-126.
20. Girodon, F., Schaeffer, C., Cleyrat, C., Mounier, M., Lafont, I., Santos, F.D., Duval, A., Maynadié, M. & Hermouet, S. (2008) Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2 V617F-positive patients within the first years of hydroxyurea therapy. Haematologica, 93, 1723-1727.
21. Goday-Fernandez, A., Boyd, E., Bench, A. & Erber, W. (2008) Real time detection of JAK2 V617F in the myeloproliferative disorders. Haematologica, 93(s1), 302. Abs.0754.
22. Grunebach, F., Bross-Bach, U., Kanz, L. & Brossart, P. (2006) Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera. Leukemia, 20, 2210-2211.
23. Guglielmelli, P., Biamonte, F., Score, J., Hidalgo-Curtis, C., Cervantes, F., Maffioli, M., Fanelli, T., Ernst, T., Winkelman, N., Jones, A.V., Zoi, K., Reiter, A., Duncombe, A., Villani, L., Bosi, A., Barosi, G., Cross, N.C. & Vannucchi, A.M. (2011) EZH2 mutational status predicts poor survival in myelofibrosis. Blood, 118, 5227-5234.
24. Harrison, C.N., Bareford, D., Butt, N., Campbell, P., Conneally, E., Drummond, M., Erber, W., Everington, T., Green, A.R., Hall, G.W., Hunt, B.J., Ludlam, C.A., Murrin, R., Nelson-Piercy, C., Radia, D.H., Reilly, J.T., Van der Walt, J., Wilkins, B. & McMullin, M.F. (2010) Guideline for investigation and management of adults and children presenting with a thrombocytosis. British Journal of Haematology, 149, 352-375.
25. Hermouet, S., Dobo, I., Lippert, E., Boursier, M.C., Ergand, L., Perrault-Hu, F. & Pineau, D. (2007) Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2 V617F. Leukemia, 21, 1128-1130.
26. Hussein, K., Bock, O., Theophile, K., Seegers, A., Arps, H., Basten, O., Grips, K.H., Franz-Werner, J., Büsche, G. & Kreipe, H. (2008) Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2 V617F mutation. Leukemia, 22, 1059-1062.
27. James, C., Ugo, V., Le Couédic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 1144-1148.
28. James, C., Delhommeau, F., Marzac, C., Teyssandier, I., Couédic, J.P., Giraudier, S., Roy, L., Saulnier, P., Lacroix, L., Maury, S., Tulliez, M., Vainchenker, W., Ugo, V. & Casadevall, N. (2006) Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia, 20, 350-353.
29. Jelinek, J., Oki, Y., Gharibyan, V., Bueso-Ramos, C., Prchal, J.T., Verstovsek, S., Beran, M., Estey, E., Kantarjian, H.M. & Issa, J.P. (2005) JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood, 106, 3370-3373.
30. Jones, A.V. & Cross, N.C. (2004) Oncogenic derivatives of platelet-derived growth factor receptors. Cellular and Molecular Life Sciences, 61, 2912-2923.
31. Jones, A.V., Kreil, S., Zoi, K., Waghorn, K., Curtis, C., Zhang, L., Score, J., Seear, R., Chase, A.J., Grand, F.H., White, H., Zoi, C., Loukopoulos, D., Terpos, E., Vervessou, E.C., Schultheis, B., Emig, M., Ernst, T., Lengfelder, E., Hehlmann, R., Hochhaus, A., Oscier, D., Silver, R.T., Reiter, A. & Cross, N.C. (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, 106, 2162-2168.
32. Jones, A.V., Silver, R.T., Waghorn, K., Curtis, C., Kreil, S., Zoi, K., Hochhaus, A., Oscier, D., Metzgeroth, G., Lengfelder, E., Reiter, A., Chase, A.J. & Cross, N.C. (2006) Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood, 107, 3339-3341.
33. Jones, A.V., Cross, N.C.P., White, H.E., Green, A.R. & Scott, L.M. (2008) Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. Haematologica, 93, 1560-1564.
34. Jovanovic, J.V., Vannucchi, A.M., Lippert, E., Oppliger Leibundgut, E., Maroc, N., Hermouet, S., Nickless, G., Cassinat, B., Guglielmelli, P., van der Reijden, B., Bench, A., Tobal, K., Wilkins, B., Cuthill, K., Ivey, A., Yeoman, K., Percy, M.J., Schwemmers, S., Gruender, A., Kelley, T.W., Reading, S., Pancrazzi, A., McMullin, M.F., Pahl, H.L., Harrison, C.N., Prchal, J.T., Chomienne, C., Kiladjian, J.J., Barbui, T. & Grimwade, D. (2011) Systematic evaluation of DNA-based quantitative-polymerase chain reaction (Q-PCR) assays to track treatment response in patients with JAK2-V617F associated myeloproliferative neoplasms: a Joint European LeukemiaNet/MPN&MPNr-EuroNet study. Blood, 118, 2812. (ASH Annual Meeting Abstracts).
35. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. & Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine, 352, 1779-1790.
36. Kroger, N., Badbaran, A., Holler, E., Hahn, J., Kobbe, G., Bornhäuser, M., Reiter, A., Zabelina, T., Zander, A.R. & Fehse, B. (2007) Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood, 109, 1316-1321.
37. Larsen, T.S., Christensen, J.H., Hasselbalch, H.C. & Pallisgaard, N. (2007) The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. British Journal of Haematology, 136, 745-751.
38. Larsen, T.S., Pallisgaard, N., Møller, M.B. & Hasselbalch, H.C. (2008) Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow. Leukemia, 22, 194-195.
39. Laughlin, T.S., Moliterno, A.R., Stein, B.L. & Rothberg, P.G. (2010) Detection of exon 12 mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing. The Journal of Molecular Diagnostics, 12, 278-282.
40. Laurent, C., Demas, V., Delabesse, E. & Brousset, P. (2007) Detection of the MPL W515L mutation in bone marrow core biopsy specimens with essential thrombocythemia using the TaqMan assay. Human Pathology, 38, 1581-1582.
41. Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S., Adelsperger, J., Koo, S., Lee, J.C., Gabriel, S., Mercher, T., D'Andrea, A., Fröhling, S., Döhner, K., Marynen, P., Vandenberghe, P., Mesa, R.A., Tefferi, A., Griffin, J.D., Eck, M.J., Sellers, W.R., Meyerson, M., Golub, T.R., Lee, S.J. & Gilliland, D.G. (2005a) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387-397.
42. Levine, R.L., Loriaux, M., Huntly, B.J.P., Loh, M.L., Beran, M., Stoffregen, E., Berger, R., Clark, J.J., Willis, S.G., Nguyen, K.T., Flores, N.J., Estey, E., Gattermann, N., Armstrong, S., Look, A.T., Griffin, J.D., Bernard, O.A., Heinrich, M.C., Gilliland, D.G., Druker, B. & Deininger, M.W. (2005b) The JAK2 V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood, 106, 3377-3379.
43. Lippert, E., Boissinot, M., Kralovics, R., Girodon, F., Dobo, I., Praloran, V., Boiret-Dupré, N., Skoda, R.C. & Hermouet, S. (2006) The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood, 108, 1865-1867.
44. Lippert, E., Girodon, F., Hammond, E., Jelinek, J., Reading, N.S., Fehse, B., Hanlon, K., Hermans, M., Richard, C., Swierczek, S., Ugo, V., Carillo, S., Harrivel, V., Marzac, C., Pietra, D., Sobas, M., Mounier, M., Migeon, M., Ellard, S., Kröger, N., Herrmann, R., Prchal, J.T., Skoda, R.C. & Hermouet, S. (2009) Concordance of assays designed for the quantification of JAK2 V617F: a multicenter study. Haematologica, 94, 38-45.
45. Ma, W., Kantarjian, H., Zhang, X., Sun, W., Buller, A.M., Jilani, I., Schwartz, J.G., Giles, F. & Albitar, M. (2008) Higher detection rate of JAK2 mutation using plasma. Blood, 111, 3906-3907.
46. Ma, W., Zhang, X., Wang, X., Zhang, Z., Yeh, C.H., Uyeji, J. & Albitar, M. (2011) MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders. Diagnostic Molecular Pathology, 20, 34-39.
47. Mason, J., Akiki, S. & Griffiths, M.J. (2011) Pitfalls in molecular diagnosis in haemato-oncology. Journal of Clinical Pathology, 64, 275-278.
48. Mattocks, C.J., Morris, M.A., Matthijs, G., Swinnen, E., Corveleyn, A., Dequeker, E., Müller, C.R., Pratt, V. & Wallace, A. (2010) A standardized framework for the validation and verification of clinical molecular genetic tests. European Journal of Human Genetics, 18, 1276-1288.
49. McClure, R., Mai, M. & Lasho, T. (2006) Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia, 20, 168-171.
50. McMullin, M.F. (2008) The classification and diagnosis of erythrocytosis. International Journal of Laboratory Hematology, 30, 447-459.
51. McMullin, M.F., Reilly, J.T., Campbell, P., Bareford, D., Green, A.R., Harrison, C.N., Conneally, E. & Ryan, K. (2007) Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. British Journal of Haematology, 138, 821-822.
52. Mead, A.J., Rugless, M.J., Jacobsen, S.E. & Schuh, A. (2012) Germline JAK2 mutation in a family with hereditary thrombocytosis. The New England Journal of Medicine, 366, 967-969.
53. Nielsen, C., Birgens, H.S., Nordestgaard, B.G., Kjaer, L. & Bojesen, S.E. (2011) The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica, 96, 450-453.
54. Pancrazzi, A., Guglielmelli, P., Ponziani, V., Bergamaschi, G., Bosi, A., Barosi, G. & Vannucchi, A.M. (2008) A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. The Journal of Molecular Diagnostics, 10, 435-441.
55. Pardanani, A.D., Levine, R.L., Lasho, T., Pikman, Y., Mesa, R.A., Wadleigh, M., Steensma, D.P., Elliott, M.A., Wolanskyj, A.P., Hogan, W.J., McClure, R.F., Litzow, M.R., Gilliland, D.G. & Tefferi, A. (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood, 108, 3472-3476.
56. Pardanani, A., Guglielmelli, P., Lasho, T.L., Pancrazzi, A., Finke, C.M., Vannucchi, A.M. & Tefferi, A. (2011) Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia, 25, 1834-1839.
57. Passamonti, F. & Rumi, E. (2009) Clinical relevance of JAK2 (V617F) mutant allele burden. Haematologica, 94, 7-10.
58. Passamonti, F., Elena, C., Schnittger, S., Skoda, R.C., Green, A.R., Girodon, F., Kiladjian, J.J., McMullin, M.F., Ruggeri, M., Besses, C., Vannucchi, A.M., Lippert, E., Gisslinger, H., Rumi, E., Lehmann, T., Ortmann, C.A., Pietra, D., Pascutto, C., Haferlach, T. & Cazzola, M. (2011) Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood, 117, 2813-2816.
59. Percy, M.J., Scott, L.M., Erber, W.N., Harrison, C.N., Reilly, J.T., Jones, F.G., Green, A.R. & McMullin, M.F. (2007) The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica, 92, 1607-1614.
60. Pieri, L., Spolverini, A., Scappini, B., Occhini, U., Birtolo, S., Bosi, A., Albano, F., Fava, C. & Vannucchi, A.M. (2011) Concomitant occurrence of BCR-ABL and JAK2 V617F mutation. Blood, 118, 3445-3446.
61. Qian, J., Lin, J., Yao, D.M., Chen, Q., Xiao, G.F., Ji, R.B., Li, Y., Yang, J. & Qian, Z. (2010) Rapid detection of JAK2 V617F mutation using high-resolution melting analysis with LightScanner platform. Clinica Chimica Acta, 411, 2097-2100.
62. Quentmeier, H., MacLeod, R.A., Zaborski, M. & Drexler, H.G. (2006) JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia, 20, 471-476.
63. Rapado, I., Grande, S., Albizua, E., Ayala, R., Hernández, J.A., Gallardo, M., Gilsanz, F. & Martinez-Lopez, J. (2009) High resolution melting analysis for JAK2 exon 14 and exon 12 mutations - A diagnostic tool for myeloproliferative neoplasms. The Journal of Molecular Diagnostics, 11, 155-161.
64. Reiter, A., Grimwade, D. & Cross, N.C. (2007) Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders. Haematologica, 92, 1153-1158.
65. Sattler, M., Walz, C., Crowley, B.J., Lengfelder, E., Jänne, P.A., Rogers, A.M., Kuang, Y., Distel, R.J., Reiter, A. & Griffin, J.D. (2006) A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples. Blood, 107, 1237-1238.
66. Schmitt-Graeff, A.H., Teo, S.S., Olschewski, M., Schaub, F., Haxelmans, S., Kirn, A., Reinecke, P., Germing, U. & Skoda, R.C. (2008) JAK2 V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica, 93, 34-40.
67. Schnittger, S., Bacher, U., Kern, W., Schröder, M., Haferlach, T. & Schoch, C. (2006) Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia, 20, 2195-2197.
68. Schnittger, S., Bacher, U., Haferlach, C., Beelen, D., Bojko, P., Bürkle, D., Dengler, R., Distelrath, A., Eckart, M., Eckert, R., Fries, S., Knoblich, J., Köchling, G., Laubenstein, H.P., Petrides, P., Planker, M., Pihusch, R., Weide, R., Kern, W. & Haferlach, T. (2009a) Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. Haematologica, 94, 141-144.
69. Schnittger, S., Bacher, U., Haferlach, C., Geer, T., Müller, P., Mittermüller, J., Petrides, P., Schlag, R., Sandner, R., Selbach, J., Slawik, H.R., Tessen, H.W., Wehmeyer, J., Kern, W. & Haferlach, T. (2009b) Detection of JAK2 exon 12 mutations in 15 patients with JAK2 V617F negative polycythemia vera. Haematologica, 94, 414-418.
70. Scott, L.M., Tong, W., Levine, R.L., Scott, M.A., Beer, P.A., Stratton, M.R., Futreal, P.A., Erber, W.N., McMullin, M.F., Harrison, C.N., Warren, A.J., Gilliland, D.G., Lodish, H.F. & Green, A.R. (2007a) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. New England Journal of Medicine, 356, 459-468.
71. Scott, L.M., Beer, P.A., Bench, A.J., Erber, W.N. & Green, A.R. (2007b) Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera. British Journal of Haematology, 139, 511-512.
72. Sidon, P., El Housni, H., Dessars, B. & Heimann, P. (2006) The JAK2 V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia, 20, 1622.
73. Skoda, R.C. (2010) Hereditary myeloproliferative disorders. Haematologica, 95, 6-8.
74. Stevenson, W.S., Hoyt, R., Bell, A., Guipponi, M., Juneja, S., Grigg, A.P., Curtis, D.J., Scott, H.S., Szer, J., Alexander, W.S., Tuckfield, A. & Roberts, A.W. (2006) Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood. Pathology, 38, 336-342.
75. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France.
76. Szpurka, H., Tiu, R., Murugesan, G., Aboudola, S., Hsi, E.D., Theil, K.S., Sekeres, M.A. & Maciejewski, J.P. (2006) Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood, 108, 2173-2181.
77. Tan, A.Y., Westerman, D.A. & Dobrovic, A. (2007) A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation. American Journal of Clinical Pathology, 127, 977-981.
78. Tefferi, A. & Vainchenker, W. (2011) Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. Journal of Clinical Oncology, 29, 573-582.
79. Tefferi, A., Noel, P. & Hanson, C.A. (2011) Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms. The Journal of Molecular Diagnostics, 13, 461-466.
80. Ugo, V., Tondeur, S., Menot, M.L., Bonnin, N., Le Gac, G., Tonetti, C., Mansat-De Mas, V., Lecucq, L., Kiladjian, J.J., Chomienne, C., Dosquet, C., Parquet, N., Darnige, L., Porneuf, M., Escoffre-Barbe, M., Giraudier, S., Delabesse, E. & Cassinat, B. (2010) Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients. PLoS ONE, 5, e8893.
81. Wang, Y.L., Vandris, K., Jones, A., Cross, N.C., Christos, P., Adriano, F. & Silver, R.T. (2008) JAK2 mutations are present in all cases of polycythemia vera. Leukemia, 22, 1289.
82. Warshawsky, I., Mularo, F., Hren, C. & Jakubowski, M. (2010) Failure of the Ipsogen MutaScreen kit to detect the JAK2 617V>F mutation in samples with additional rare exon 14 mutations: implications for clinical testing and report of a novel 618C>F mutation in addition to 617V>F. Blood, 115, 3175-3176.
83. Williams, D.M., Kim, A.H., Rogers, O., Spivak, J.L. & Moliterno, A.R. (2007) Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Experimental hematology, 35, 1641-1646.
84. Wong, C.L., Ma, E.S., Wang, C.L., Lam, H.Y. & Ma, S.Y. (2007) JAK2 V617F due to a novel TG-CT mutation at nucleotides 1848-1849: diagnostic implication. Leukemia, 21, 1344-1346.
85. Wu, Z., Yuan, H., Zhang, X., Liu, W., Xu, J., Zhang, W. & Guan, M. (2011) Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera. PLoS ONE, 6, e26534.
86. Xu, X., Zhang, Q., Luo, J., Xing, S., Li, Q., Krantz, S.B., Fu, X. & Zhao, Z.J. (2007) JAK2(V617F): prevalence in a large Chinese hospital population. Blood, 109, 339-342.
87. Yokota, M., Tatsumi, N., Nathalang, O., Yamada, T. & Tsuda, I. (1999) Effects of heparin on polymerase chain reaction for blood white cells. Journal of Clinical Laboratory Analysis, 13, 133-140.